Europe’s Payers Bake Indication-Specific Pricing Into Benefit Assessments
European countries haven’t grappled with indication-specific pricing, mostly because they haven’t had to.
You may also be interested in...
Indication-based drug pricing is one mechanism for pegging price to value. It will be tough to implement in the US without systemic change, but PBMs have plenty of incentives to make it work.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.